Novartis Ritalin LA clears FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis adds second once-daily methylphenidate product with the June 5 approval of Ritalin LA, to be launched by the beginning of the 2002-2003 school year. The drug, developed using Elan's Spheroidal Oral Drug Absorption System (SODAS), has a bi-modal release, with half the dose in immediate-release beads and half in delayed-release beads that provide methylphenidate four hours later. Ritalin SR, in contrast, provides continuous drug release over eight hours. Ritalin LA will be available in 20 mg, 30 mg and 40 mg capsules that can be sprinkled onto applesauce, while Ritalin SR is available in 20 mg tablet
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.